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ABSTRACT 
Replication of some HPV types is modulated by cAMP-dependent protein kinase activity 
Human papillomaviruses (HPVs) are dsDNA viruses infecting basal keratinocytes of the 
cutaneous and mucosal epithelia. Some HPVs are tumorigenic; therefore, studies of the viral 
life cycle may help to develop novel treatment strategies. Protein kinases are important enzymes 
that regulate numerous cellular processes. HPV E1 and E2 regulatory proteins have several 
putative consensus sites for many kinases including cAMP-dependent protein kinase (PKA). 
The main focus of this thesis was to generate the constructs encoding the FLAG-tagged PKA 
catalytic subunit α (PKACα) and its two catalytically deficient mutants, and to investigate the 
influence of the over-expressed PKA proteins on replication of HPV types 5, 11, and 18 in 
U2OS cells. Additionally, PKA activator IBMX and inhibitor H89 were used to demonstrate 
the impact of the endogenous PKA catalytic activity on the replication efficiency of the HPV5 
genome. Finally, the mechanism of the PKA-mediated stimulation of the HPV18 replication 
was studied.  
Keywords: human papillomavirus (HPV), replication, transcription, protein kinase A (PKA)  
CERCS: B230 Microbiology, bacteriology, virology, mycology 
 
Mõnede HPV tüüpide replikatsioon on moduleeritud cAMP-sõltuva proteiinkinaasi 
aktiivsuse poolt 
Inimese papilloomiviirused (HPV) on kaheahelalise DNA genoomiga viirused, mis nakatavad 
basaalseid keratinotsüüte nahas ja limaskestades. Mõned HPV tüübid omavad kõrget 
onkogeenset potentsiaali, seetõttu on viiruse elutsükli uurimine tähtis uute ravistrateegiate 
arendamiseks. Proteiinkinaasid modifitseerivad oma märklaudvalkude aktiivsust ning seega 
reguleerivad paljusid bioloogilisi protsesse rakkudes. HPV E1 ja E2 on viiruslikud 
regulatoorsed valgud, mis sisaldavad mitu oletatavat cAMP-sõltuva proteiinkinaasi (PKA) 
konsensus saiti. Selle töö eesmärk oli luua plasmiidid, mis kodeerivad FLAG-märgisega PKA 
katalüütilist subühikut α (PKACα) ja tema kahte katalüütiliselt inaktiivset mutanti, ja uurida 
PKA valkude üle-ekspressiooni mõju HPV tüüp 5, 11, 18 replikatsioonile U2OS rakkudes. 
Lisaks, testiti PKA aktivaatori IBMX ja inhibiitori H89 mõju HPV5 replikatsioonile ning 
selgitati välja PKA-st sõltuva HPV18 replikatsiooni aktivatsiooni mehhanism.  
Märksõnad: inimese papilloomiviirus (HPV), replikatsioon, transkriptsioon, proteiinkinaas A 
(PKA) 
CERCS: B230 Mikrobioloogia, bakterioloogia, viroloogia, mükoloogia  
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LIST OF ABBREVIATIONS 
AKAP - A-kinase anchoring proteins 
Amp – ampicillin 
AP – alkaline phosphatase 
BCC – basal cell carcinoma 
BPV – bovine papillomavirus 
BS – binding site 
C – catalytic (subunit) 
CDK – cyclin-dependent kinase 
CK2 – casein kinase II 
cDNA – complementary DNA 
CREB - cAMP-responsive element binding protein 
dsDNA – double-stranded DNA 
E2Fs - transcription factors involved in cell cycle regulation 
E2-TA – full-length E2 protein 
E – early (genomic region or protein) 
FGFR3 - fibroblast growth factor receptor 3 
H89 - n-[2-p-bromocinnamylamino-ethyl]-5-isoquinolinesulfonamide 
HPV – human papillomavirus 
HR – high-risk (papillomavirus) 
HSPG - heparan sulfate proteoglycan 
IBMX - 3-isobutyl-1-methyl-xanthene 
K72R – lysine residue at position 72 mutated to arginine 
KAB – kinase assay buffer 
L – late (genomic region or protein) 
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LR – low-risk (papillomavirus) 
MAPK – mitogen activated protein kinase 
NGM – normal growth medium 
ORF – open reading frame 
PDE – phosphodiesterase 
PEI – polyethyleneimine 
PKA - cAMP-dependent protein kinase 
PKC - protein kinase C 
PKACα - catalytic subunit α of PKA 
PKA C – catalytic subunits of PKA 
PKG - cGMP-dependent protein kinase 
pRb – retinoblastoma protein  
PV – papillomavirus 
R – regulatory (subunit) 
RT – room temperature 
SB – southern blot 
SCC – squamous cell carcinoma 
T197A - threonine residue at position 197 mutated to alanine 
URR – noncoding upstream regulatory region 
WB – western blot 
WR – working reagent  
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INTRODUCTION 
Human papillomaviruses (HPVs) are double-stranded DNA (dsDNA) viruses infecting 
epithelial keratinocytes of mucosa or skin. HPV infection is among the most common sexually 
transmitted diseases worldwide. Different types of HPVs are divided into high- and low-risk, 
depending on presence or absence of an oncogenic potential (Rosa et al., 2013). The medical 
importance of studying the life cycle of HPVs and their interactions with host cells is 
attributable to the absence of drugs against HPV infections.  
Inhibition of HPV replication is one of the promising therapeutic strategies for the treatment of 
HPV-related diseases. However, in order to interfere with viral life cycle and avoid damaging 
the host cells, it is essential to understand the interplay between HPV and the host cell in 
molecular terms. Protein kinases are important regulators of diverse biological processes in the 
cells. HPV key replication proteins E1 and E2 are found to be substrates for many cellular 
kinases, including cAMP-dependent protein kinase (PKA). Many of these kinases are known 
to regulate HPV replication in a HPV type-dependent manner (Ma et al., 1999; Piirsoo et al., 
2019; Xie et al., 2017; Yu et al., 2007; Zanardi et al., 1997).  
The aim of this study was to investigate the impact of the catalytic subunit α of PKA (PKACα) 
on replication of HPV types 5, 11 and 18. The chosen HPV types belong to different genera 
and risk groups. In order to prove that PKA acts in a kinase activity-dependent manner, we 
generated plasmids encoding for PKACα and its two catalytically deficient mutants, 
PKA(T197A) and PKA(K72R). The first part of this thesis provides an overview of the HPV 
infection cycle and functions of the viral proteins, and describes the roles of PKA in both host 
cells and viral life cycle. The experimental part describes the generation of the FLAG-tagged 
PKA expression constructs and the analysis of the viral genome replication in the presence of 
the over-expressed PKA proteins, and provides an explanation of the possible mechanisms of 
the PKA-mediated activities. We show that the over-expressed catalytically active PKA has a 
different impact on the viral replication depending on the type of the HPV. Furthermore, the 
present study demonstrates that efficiency of the viral genome replication may be affected by 
endogenous PKA activity, either potentiated with 3-isobutyl-1-methyl-xanthene (IBMX) or 
suppressed with n-[2-p-bromocinnamylamino-ethyl]-5-isoquinolinesulfonamide (H89). This 
study was performed in the molecular virology research group, Institute of Technology, 
University of Tartu. 
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1. LITERATURE OVERVIEW 
1.1. Papillomaviruses and human papillomaviruses 
Papillomaviruses (PVs) are small non-enveloped icosahedral viruses with circular dsDNA 
genomes approximately 5-8 kb in size typically containing up to eight genes. PVs belong to 
Papillomaviridae family, and according to the International Committee on the Taxonomy of 
Viruses, there are two subfamilies Firstpapillomavirinae, which includes over 50 genera (from 
Alpha- to Zetapapillomavirus) and more than 130 species, and Secondpapillomavirinae with a 
single genera and a unique specie (Van Doorslaer et al., 2018). The classification is based on 
pairwise sequence alignment identity across the open reading frame (ORF) of L1, which 
encodes the major capsid protein L1 is one of the most conserved genes among PVs. In order 
to be classified as a novel PV type, the nucleotide sequence of L1 must be at least 10% dissimilar 
from that of any other PV (de Villiers et al., 2004).  
PVs infect epithelial keratinocytes in large variety of animals, where they can persist 
asymptomatically or cause neoplasms (Bernard et al., 2010). Wide range of vertebrate species 
can be infected by PVs: mammals, birds, reptiles and fish (Herbst et al., 2009; López-Bueno et 
al., 2016; Terai et al., 2002; de Villiers et al., 2004). HPVs are a diverse group of PVs with 
over 200 different types being described, and new HPV types being continuously found 
(Papillomavirus Episteme database). HPV types are phylogenetically organized into five major 
genera: alpha- (α), beta- (β), gamma- (γ), mu- (μ), and nu- (ν) PVs (de Villiers et al., 2004). 
HPVs infect mucosal and cutaneous epithelia: the members of the α genus are associated with 
infections of oral and genital mucosal surfaces and external genitalia, while β, γ, μ, and ν genera 
HPVs infect non-genital mucosa and skin (Rosa et al., 2013). HPVs can be additionally divided 
into high- and low-risk (HR and LR, respectively) types according to their ability to induce 
benign hyperplasia and trigger their progression to malignancy (Cubie, 2013).  
HR HPV types include 16, 18, 31, 33, 35, 39, 45, 51, 52, 55, 56, 58, 59, 68, 73, 82, 83. HR 
HPVs are found in different invasive cancer specimens (Gillison and Shah, 2003). For example, 
mucosal types of HPV α genus are a major cause of cervical cancer (Walboomers et al., 1999) 
with HPV16 accounting for over 50% and HPV16 and 18 for >70% found in invasive cervical 
cancer histological specimens worldwide (Li et al., 2011). In addition, types from α genus are 
associated with head and neck cancers (Leemans et al., 2011), increased risk of oral cavity and 
oropharyngeal cancer (Anantharaman et al., 2013). HPVs are also associated with other 
anogenital cancers such as anal, vulvar and penile cancers with the prevalence of HPV16 and 
HPV18 (Daling et al., 2004; McCance et al., 1986; de Sanjosé et al., 2013).  
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Keratinocytes-derived non-melanoma skin cancers (Small et al., 2016) can be divided into basal 
cell carcinoma (BCC) and squamous cell carcinoma (SCC) (El-Abaseri et al., 2006). It was 
previously shown that genus‐β HPV infections may contribute to SCC (Iannacone et al., 2014) 
and BCC development (Iannacone et al., 2013). DNA of cutaneous HPV types was found in 
biopsies from patients with SCC of the conjunctiva (Ateenyi-Agaba et al., 2010). HPVs from 
this genus are also associated with skin cancer in patients with epidermodysplasia verruciformis 
– a rare autosomal recessive skin disorder that increases the risk of developing HPV-induced 
SCC (Orth, 2006).  
HPVs of γ, μ, and ν genera cause warts or cutaneous papillomas (de Villiers et al., 2004), and 
there is little to no evidence of their involvement in tumorigenesis. HPVs can also be found in 
healthy skin: DNA of β HPV types can be detected in babies after a few days of life (Antonsson 
et al., 2003). One of the articles suggests that the prevalence of β HPVs increases with age in 
healthy individuals without inducing SCC (de Koning et al., 2009).  
 
1.2. HPV genome and viral proteins 
Different HPV types have similar genome organization. Schematic representation of HPV 
genomes used in the present study are shown in Figure 1. Although the viral genome can vary 
in size between different types, it typically contains around 8000 bp (Doorbar, 2006). The 
genomes can be divided into three different regions: early (E), late (L) and noncoding upstream 
regulatory region (URR) also called long control region (LCR) located between them. Most 
types of HPVs contain eight ORFs coding 6 early and 2 late proteins. Furthermore, HPVs 
encode several truncated forms of proteins translated from alternatively spliced transcripts (e.g. 
E1^E4 and E8^E2C). The early proteins mostly play regulatory role, for example, participate 
in viral replication and transcription. The late proteins are involved in virus capsid formation 
(Graham, 2010). 
URR is approximately 500 to 1000 bp region located upstream of the coding region. It contains 
the replication origin (ori), transcriptional enhancer and promoter elements, binding sites (BSs) 
for cellular transcription factors and viral proteins E1 and E2, which are all involved in the 
control of the viral gene expression (McBride, 2008). Polycistronic transcripts are synthesized 
from only one DNA strand, then undergo alternative splicing and may be subjected to 
alternative polyadenylation resulting in a huge variety of different functional mRNAs. URR 
contains also early and late promoters - regions in which the synthesis of early or late transcripts, 
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respectively, is initiated, and polyadenylation sites for the late transcripts (Baker and Calef, 
1996). 
 
Figure 1. Schematic representation of HPV5, HPV11 and HPV18 reference genomes. Early ORFs (E1, E2, E5, 
E6, and E7 – indicated by green), late ORFs (L1 and L2 - shown in blue) and URR region (yellow). HPVs encode 
truncated forms of proteins using alternatively spliced pre-mRNAs (E1^E4 and E8^E2C - orange and pink). URR 
contains regulatory sequences and binding sites (BSs) for viral and cellular proteins (shown in red, blue and purple) 
(Papillomavirus Episteme database). 
1.2.1 Early region proteins 
The E1 protein is approximately 70 kDa ATP-dependent helicase that binds specifically to the 
ori and initiates replication (Yang et al., 1993). The E1 protein consist of the N-terminal 
domain, central domain and the C-terminal domain (McBride, 2008). The N-terminal domain 
is a regulatory region essential for optimal replication; the central domain recognizes specific 
sites in the ori and binds to the DNA; the C-terminus is an enzymatic domain, which is 
necessary for self-assembly into hexamers and for unwinding short DNA duplexes. E1 interacts 
with E2 and specific host factors to coordinate the assembly of a functional viral replisome 
(Bergvall et al., 2013). 
The E2 is around 50 kDa regulatory protein (Rajkumar, 2016). E2 gene products vary in size 
as a result of expression from different promoters and/or alternative RNA splicing. These 
alternatively named proteins (E8^E2, E8^E2C, E1^E2, E1M^E2 and E9^E2) function as 
repressors of viral transcription and replication (McBride, 2013). The full-length E2 (E2-TA) 
can influence the transcription of HPV genes both positively and negatively (Steger and 
Corbach, 1997). The E2 proteins play an important role in the maintenance of the viral genome 
as an independent episomal element (Ilves et al., 1999). E2 directs E1 to the ori region by 
increasing the E1 ori-binding specificity (Sedman and Stenlund, 1995). It regulates pre-mRNA 
processing (possibly via interacting with cellular splicing factors); induces cell apoptosis and 
 11 
suppresses cellular growth through modulation of the E6 and E7 expression (Dowhanick et al., 
1995; Lai et al., 1999; Webster et al., 2000).  
The E4 protein is usually expressed from E1^E4 spliced transcript. E4 ORF is located in E2 
gene and also contains few nucleotides and the initiation codon of E1 (Doorbar, 2013). The E4 
protein influences the cell cycle along with E5, E6 and E7 oncoproteins (Davy et al., 2002). E4 
interacts with E2 and promotes its relocation to the cytoplasm changing the availability at 
different times during the viral life cycle (Davy et al., 2009). The Abovementioned mechanisms 
are important for effective amplification of viral DNA. E4 also increases the egress of PV 
virions (Doorbar et al., 1991).  
E5 is a short membrane-associated protein with transforming activity, typically mediating 
specific protein-protein interactions (DiMaio and Petti, 2013). The majority of HPV types 
encodes distinct forms of E5 protein: HR HPVs encode E5 α, which is associated with the 
progression of tumor development, whereas LR HPVs either lack E5 or express different 
polymorphic types of the protein (E5 β, -γ, -δ) and most likely lead to non-tumoral outcomes 
(Bravo and Alonso, 2004). The E5 protein is also associated with modulation of the host 
immune response (Grabowska and Riemer, 2012), and has the ability to enhance signal 
transduction from epidermal growth factor to the nucleus resulting in increased cell 
proliferation (Bouvard et al., 1994; Leechanachai et al., 1992; Stöppler et al., 1996). 
The E6 is one of the PV oncoproteins with transforming abilities. E6 consists of approximately 
150 amino acids and contains two zinc-finger binding motifs (Lipari et al., 2001). The E6 
protein promotes cell proliferation through degradation of p53 tumor suppressor protein 
(Scheffner et al., 1990). The E6 proteins produced by HR HPVs has higher affinity to p53 than 
LR ones (Li and Coffino, 1996), which can be one of the reasons of the high oncogenic activity 
of HR HPVs. One of the targets of HR E6 is the tumor suppressor protein DLG, which 
participates in regulation of cell adhesion, polarity, proliferation in epithelial tissues and 
formation of junctions between cells (Bilder et al., 2000). Deregulation of the DLG protein 
leads to invasive cell growth (Kiyono et al., 1997).  
E7 is also PV oncoprotein with transforming properties. E7 is approximately 10-14 kDa 
(Rajkumar, 2016). E7 induces cellular proliferation through association with the tumor 
suppressor protein pRb (retinoblastoma protein) (Dyson et al., 1989). E7 disrupts natural 
formation of pRb and the cellular transcription factor (E2F) complex, resulting in increased 
production of active E2Fs (Chellappan et al., 1992). This mechanism suggests that HPVs are 
able to reactivate host DNA replication machinery in already differentiated cells (Cheng et al., 
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1995). The E6 and E7 oncoproteins were shown to induce mitotic defects, genomic instability 
and centrosomal abnormalities in host cells by coupling with pRb-related proteins (p107 and 
p130) (Duensing et al., 2000). 
The E8^E2 is a fusion protein generated by splicing a short E8 exon to the major splice acceptor 
in the middle of the E2 ORF. As the E2-TA protein, E8^E2 also inhibits transcription of the 
viral major early promoter but more efficiently: it represses not only the expression of the HPV 
E6 and E7 oncoproteins, but also E1 and E2 replication proteins (Stubenrauch et al., 2000).  
1.2.2 Late region proteins 
Icosahedral PV virions consist of two proteins: L1 and L2 (Buck et al., 2008). L1 is the major 
capsid antigen, which is displayed on the surface of the virion (Buck et al., 2013). The L1 
protein can self-assemble into virus-like particles, forming the native structure of PV virions 
(Kirnbauer et al., 1992). L2 or minor capsid protein, is hidden inside the mature capsid, whereas 
only a part of its N-terminus is exposed on the surface, playing role in the interactions with the 
host cell (Joyce et al., 1999; Liu et al., 1997). In addition, L2 is essential in the process of virion 
assembly (Holmgren et al., 2005). 
 
1.3. HPV infection cycle 
HPV infection occurs in basal keratinocytes of the stratified epithelium, which is able to 
proliferate constantly. Therefore, HPV cycle is tightly linked to the normal differentiation 
process of the host keratinocytes. The viral particle invades the basal layer through micro-
wounds of the skin surface or via hair follicles (Kines et al., 2009; Schmitt et al., 1996). Virions 
interact with the heparan sulfate proteoglycans (HSPGs) and yet uncharacterized secondary 
specific receptors on the surface of basal keratinocytes, and then enter the cell (Kines et al., 
2009). The hypothetical model suggests that the initial interaction between L1 and the host cell 
surface HSPGs causes conformational change in L1 and exposure of the N-terminus of L2, 
allowing its cleavage and interaction with the host cell secondary and, probably, entry receptors 
(Day et al., 1998; Joyce et al., 1999). Conformational changes in the viral capsid allow viral 
DNA to be transported to the nucleus (Kämper et al., 2006; Li et al., 1998), where the HPV 
genome is amplificated, then maintained at a low-copy number, and later, in the vegetative 
replication phase, is amplified to a high-copy number, in order to be packed into new virions 
and egress from the host cell (Figure 2) (Fisher, 2015).  
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Figure 2. The phases of the replication of HPV (Fisher, 2015).  
1.3.1 Initiation of viral DNA replication and genome maintenance  
The E1 protein has an ATPase and helicase activity: it unwinds dsDNA, recruits host replication 
factors (DNA polymerase α/primase, replication protein A and topoisomerase I) and initiates 
viral replication (Burley et al., 2020; Wilson et al., 2002). E2-TA binds to BSs - 12 bp 
(ACCGN4CGGT) palindromic sequences, which are present in multiple copies within the URR 
(Hirochika et al., 1988) and loads E1 protein onto the ori site; however, E2 must dissociate 
from the complex for the viral DNA replication to start (Sanders and Stenlund, 1998). 
Oligomerization of E1 and dissociation of E2 from the E1-E2-ori complex is stimulated by ATP 
(Titolo et al., 2000). The replication is initiated bidirectionally via theta model (Flores and 
Lambert, 1997). 
E2-TA can act as an activator of HPV gene transcription or as a repressor depending on the 
dose of E2 product, context of BS and nature of associated cellular factors, which are recruited 
by the virus (Muller and Demeret, 2012; Steger and Corbach, 1997). Low amounts of E2 bind 
to the most distal BS with high-affinity (BS-4) and activate the early promoter of HPV18 (p105) 
generating early proteins. In high concentrations, E2 binds also to the sites with the reduced 
affinity (BS-1, 2, 3) resulting in early promoter repression (Steger and Corbach, 1997). Binding 
of E2 proteins to its multiple BSs and chromatin is required for maintenance of the viral DNA 
as an episome or independent cell element and segregation of the HPV genome evenly among 
daughter cells during mitosis (Ilves et al., 1999).  
The E8^E2 protein is one of the proteins, which regulate viral cycle and is also important for 
the maintenance of low-copy number strategy. It inhibits transcription of the viral major early 
promoter, additionally recruiting cellular corepressors such as histone deacetylases 
(Ammermann et al., 2008; Stubenrauch et al., 2000). E8^E2 is able to form a complex with E2-
TA and to bind to E2 BS in the URR (Kurg et al., 2010). Formation of the E8^E2/E2 complex 
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excludes the E1 protein from the ori, which strongly represses HPV replication. The E8 
promoter region can be either inhibited by E8^E2 or weakly activated by E2 suggesting that 
this promoter can act as a modulator for viral copy number (Straub et al., 2015).  
1.3.2 Viral genome amplification  
After leaving the basal membrane, cells initiate the differentiation program, exit from the cell 
cycle and suppress DNA replication activity. Since the virus does not encode DNA polymerase, 
it requires host DNA replication machinery to replicate its DNA, and therefore HPV must 
reactivate cell division (Figure 3). 
 
 
Figure 3. The key events and viral gene expression in a differentiating epithelium during the life cycle of HPV. 
Virus is shown as red pentagon and its genome as black circle. Shading on the arrows represents the quantity of 
expression of each protein during the viral replication cycle (Burley et al., 2020).  
Active HPV DNA amplification occurs not only in the S but also in the G2 phase of cell cycle, 
to avoid competing with host DNA replication during S phase. The E4 protein targets the host 
cell machinery arresting the cell cycle progression in G2 phase (Davy et al., 2002). In addition, 
E7 activates DNA damage repair pathways to use it for its own genome replication purposes 
(Moody and Laimins, 2009). Vegetative replication phase progresses to active phase and theta 
structures change to unidirectional rolling-circle mode, which allows to generate large amounts 
of viral DNA copies (Flores and Lambert, 1997). 
1.3.3 Genome packaging and egress of the virions 
The late stages occur in the upper layers of the stratified epithelium, where the viral copy 
number increases to several thousand copies per cell (Bedell et al., 1991). The E7 proteins are 
important for HPV late promoter activation (Bodily et al., 2013). The expression of genes 
involved in replication is accelerated in order to provide high number of viral copies to be 
packed in newly synthesized virions (Hummel et al., 1992; Ozbun and Meyers, 1997). The E8 
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promoter, however, remains active in the late stages of viral cycle, which means that the E8^E2 
protein can still act as a repressor and modulate HPV genome amplification (Dreer et al., 2017).  
The whole cascade of events triggers the synthesis of capsid proteins, while L2 synthesis occurs 
prior to L1 (Becker et al., 2003). At the same time, E2 recruits viral genomes to the sites of 
virus assembly (Day et al., 1998). The evidence suggests that L2 affects the viral DNA 
encapsidation process and recruits L1 protein for efficient packaging (Holmgren et al., 2005). 
Then, the progenitor virions are released externally with peeled keratinocytes. The E4 protein 
increases the egress of PV virions by remodeling the cytokeratin network of the cell and even 
inducing disruption, when overexpressed (Doorbar et al., 1991).  
1.3.4 Phosphorylation of HPV proteins and host-provided viral cycle regulation 
Protein kinases are enzymes that modify other proteins in the cell by transferring the phosphate 
from ATP to amino acid side chains. In eukaryotes, most protein kinases phosphorylate either 
Ser/Thr or Tyr, and a few of them phosphorylate all three amino acids. Phosphorylation usually 
triggers functional changes in the target proteins (referred in literature as substrates) such as 
changes of their enzymatic activity, cellular location, or their ability to interact with other 
proteins. The catalytic domain contains an active site with ATP binding pocket, where ATP is 
bounded and then hydrolyzed. In addition, most protein kinases have other domains required 
for the regulation of catalytic activity, interactions with other proteins or subcellular localization 
(Pollard et al., 2017).  
Both E1 and E2 are phosphorylated by host protein kinases. Casein kinase II (CK2) plays a role 
in regulation of cell cycle, cellular division, survival and apoptosis (Litchfield, 2003). 
Interestingly, CK2 phosphorylates the N-terminal domain in the E1 protein and the hinge region 
in the E2 protein. Phosphorylation of E1 of HPV11 and HPV31 and E2 of BPV1 (bovine 
papillomavirus) resulted in inactivation of their DNA binding activity that imply CK2 as a 
negative regulator of viral replication (Schuck et al., 2013). In contrast, CK2-mediated 
phosphorylation of BRD4 (cellular chromatin-binding factor) is required for its interaction with 
HR HPV E2 proteins being critical for viral life cycle: replication initiation, gene transcription, 
viral genome segregation and maintenance during mitosis (Iftner et al., 2017). Also, 
knockdown of CK2α or inhibition of its catalytic activity was shown to downregulate HPV5, 
HPV11 and HPV18 replication indicating that CK2 activity is required for the life cycles of 
some HPV types (Piirsoo et al., 2019). 
Mitogen-activated protein kinases (MAPKs) participate in different signal transduction 
pathways that control numerous intracellular events (Pearson et al., 2001). Phosphorylation of 
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the HPV11 E1 nuclear localization sequences by MAPK is required for the protein import to 
the nucleus to support viral DNA replication. This mechanism is suggested to be important for 
the establishment of persistent HPV infection (Yu et al., 2007).  
Cyclin-dependent kinases (CDKs) regulate cell division and transcription in response to extra- 
and intracellular stimuli, and are characterized by requirement of cyclin – a separate unit 
providing domains for enzymatic activity (Malumbres, 2014). The E1 protein was previously 
shown to be able to interact with cyclins and therefore with CDK. E1 nuclear export signal is 
inactivated while phosphorylated by CDK, and therefore the protein remains in the nucleus, 
allowing for regulation of viral DNA replication (Deng et al., 2004; Ma et al., 1999). 
Fibroblast growth factor receptor 3 (FGFR3) regulate cell growth, differentiation and migration, 
depending on cell type and its developmental stage. Interestingly, mutations activating FGFR3 
kinase activity are associated with different tumor types including skin and cervix (Logié et al., 
2005). FGFR3 colocalize with HPV E2 protein in the nucleus and phosphorylates it, restricting 
viral replication during early stages of infection. As cell differentiates, FGFR3 expression 
decreases, permitting viral genome amplification (Xie et al., 2017).  
The AGC group of kinases and in particular PKA was shown to have an effect on PV proteins. 
The serine residue 109 of BPV E1 protein is a target for PKA, and mutation of this position 
reduces viral replication. However, the exact mechanism remained unclear (Zanardi et al., 
1997). The serine 253 of the forced-expressed HPV8 E2 protein is most likely phosphorylated 
by PKA. The Phosphorylated protein has longer half-life, being stabilized by binding to host 
chromatin, from S-phase and through mitosis (Sekhar and McBride, 2012). However, this 
phosphorylation seemed to be useless for HPV8 replication in U2OS cells. 
 
1.4. Protein kinase A 
The AGC group is a subgroup of the Ser/Thr kinases named after 3 representative families: the 
cAMP-dependent protein kinase (PKA), the cGMP-dependent protein kinase (PKG) and the 
protein kinase C (PKC) (Hanks and Hunter, 1995). In addition, each family has multiple 
isoforms and splice variants, making the system of regulatory kinases even more complex.  
1.4.1 PKA structure and regulation of activation 
The PKA holoenzyme exists as a tetramer, comprised of two regulatory (R) subunits and two 
catalytic subunits (C) (Krebs and Beavo, 1979). The catalytic subunits Cα and Cβ are encoded 
by PRKACA and PRKACB genes, while Cγ (encoded by PRKACG) is expressed only in germ 
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cells in the human testis (Reinton et al., 1998; Søberg et al., 2013). The PKA subunits have 
several isoforms due to alternative splicing. There are two distinct types of PKA, type I and II, 
each of them contains either RI or RII type of R subunit, respectively. In addition, each of type 
of R subunit has two isoforms: RIα, RIβ, RIIα, and RIIβ (Corbin et al., 1977, 1978). The RI 
and RII classes have different sensitivity to cAMP, phosphorylation patterns and subcellular 
localization (Cadd and McKnight, 1989). 
A-kinase anchoring proteins (AKAP) are functionally related family of proteins, containing 
“anchoring motifs”, which binds R subunit of PKA, and “targeting domain”, which associates 
PKA-AKAP complex with cellular organelles, membranes or structural proteins. AKAPs allow 
to place PKA closely to target substrates and enzymes, which regulate its activation and 
inactivation (Dell’Acqua and Scott, 1997). AKAP function is essential for controlling PKA 
function as PKA itself lacks localization domains. 
As it is described in the name, PKA activity depends on cellular levels of cAMP, a second 
messenger synthesized by adenylate cyclase from ATP, which is able to modulate many cellular 
functions and the activation of PKA in particular (Kamenetsky et al., 2006). The release of 
cAMP occurs in response to stimulation of the receptor by a first messenger. The cAMP binds 
to the R subunits of the enzymatically inactive PKA holoenzyme localized in the cell cytoplasm, 
thereby liberating the catalytically active C subunits for phosphorylation of the protein 
substrates in cytosol and nucleus (Hunter, 2000). Activity of the PKA is regulated by the level 
of cAMP in the cytosol, and any change in concentration directly influences the PKA activity. 
Modulation of PKA activity occurs by a complex feedback mechanism. The level of cAMP can 
be decreased by phosphodiesterases (PDEs), which hydrolyze cAMP and therefore have a 
negative impact on PKA activity (Plattner and Bibb, 2012). Phosphatases have an ability to 
modulate both the phosphorylation of PKA subunits and counteract to PKA by 
dephosphorylating the target proteins (Burdyga et al., 2018). In addition, activation of PKA is 
regulated by complex phosphorylation events, such as autophosphorylation and 
phosphorylation by other regulatory kinases (for example, phosphoinositide-dependent kinase 
- PDK1) (Byrne et al., 2016; Cheng et al., 1998).  
PKA core consists of N-lobe and C-lobe, forming a cleft for both ATP and target substrate 
binding (Figure 4). The N-terminus accommodates the ATP molecule, and conserved lysine 72 
(K72) was shown to be important for stabilization of both the hydroxyl group of the substrate 
and the phosphate. Highly conserved DFG motif forms contact with all three ATP phosphates 
through Mg2+ ions and conserved D184 position. The DFG phenylalanine forms contact with 
HRD motif in the C-lobe, where conserved D166 position corrects the orientation of peptide 
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substrate. One of the main conserved positions in the core is phospho-threonine 197 (T197), 
which helps to secure the contact of the substrate and ATP molecule (Johnson et al., 2001; 
Kornev et al., 2006; Meharena et al., 2013).  
 
Figure 4. PKA core structure with associated ATP and substrate. The right part of the picture can be referred as 
the activation or catalytic segment. The phosphates are shown in red; hydroxyl group of the protein substrate is 
shown in brown; important contacts are shown by dashed lines (Kornev et al., 2006). 
The cleft also contains glycin-rich loop, which is essential for γ-phosphate transfer from ATP 
to the substrate (Kornev et al., 2006). Typically, each protein kinase has a strict number of 
substrates. All of them have a consensus target sequence, which consists of similar residues 
surrounding the target Ser/Thr. The PKA C subunits phosphorylate these residues in the 
sequence context of R-R/K-X-S/T (X represents any amino acid) (Kemp et al., 1977; Kennelly 
and Krebs, 1991). Hydroxyl group of the Ser/Thr residue of the target peptide should be facing 
the γ-phosphate of the ATP. Lastly, the terminal phosphate is transferred to the recipient 
substrate, and both phosphorylated substrate and ADP are released from the kinase (Kornev et 
al., 2006).  
1.4.2 PKA role in cell  
Major physiological functions of PKA include glucose homeostasis and triglyceride storage 
(Czech et al., 2013). PKA pathway interacts with other pathways and influences different signal 
mechanisms (Robinson‐White and Stratakis, 2002), for example, PKA acts as a feedback 
inhibitor for cAMP through phosphorylation of cAMP-responsive element binding protein 
(CREB) in the nucleus, activating CREB pathway (Shabb, 2001; Xia et al., 2009). PKA 
pathway influences proliferation of different cell types (Bacallao and Monje, 2013; Cheadle et 
al., 2008; Kim et al., 2012) and regulates cell migration due to the ability of PKA to interact 
with cell factors that control Ca2+ flux (Howe, 2011). Also, that the inflammatory response is 
regulated PKA-dependently through localization and coordination of macrophages (Wall et al., 
2009). 
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1.5. Reasons to study 
HPV is considered to be one of the most widespread sexually transmitted infections worldwide, 
suggesting that more than 80% of men and women acquire HPV by age 45 years (Chesson et 
al., 2014; de Sanjosé et al., 2007). Pap test (Papanicolau test) is routinely performed screening 
method, which can be used to detect atypical cells in cervicovaginal smears, and is considered 
to be the most important preventive measure for cervical carcinoma. However, co-testing with 
other methods is recommended in order to decrease the rate of false-negative results. Therefore, 
molecular tests to detect HPV DNA, RNA or proteins are being developed and becoming 
available (Kroupis and Vourlidis, 2011).  
Nowadays, vaccination is the main strategy for prevention of the HPV-related cancers. The 
vaccine is produced by inserting the L1 gene into a host (either yeast or baculovirus vector) to 
produce L1 major capsid proteins, which then self-assemble into virus like particles. Several 
prophylactic vaccines are available and approved for use, such as bivalent vaccine produced by 
GlaxoSmithKline (Cervarix) containing HPV16 and HPV18 antigens, and the quadrivalent 
vaccine produced by Merck (Gardasil) containing HPV6, HPV11, HPV16, and HPV18 
antigens. Both Gardasil and Cervarix were shown to provide nearly 100% protection against 
persistent cervical infections with HPV16 and HPV18. Expanded nonavalent vaccine Gardasil 
9 was recently approved by FDA. The vaccine is preventive against HPV types 6, 11, 16, 18, 
31, 33, 45, 52, and 58 (Herrero et al., 2015). 
At the moment, very little is known about the role of PKA in the life cycle of different HPV 
types; however, the information obtained from various articles suggests that PKA may 
somehow modulate HPV replication and, if proceed from this premise, this study can contribute 
to the better understanding of this interplay.  
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2. EXPERIMENTAL PART 
2.1. Aims of the study 
The general aim of this thesis was to investigate the influence of the PKACα on replication of 
HPV types 5, 11, 18 in U2OS cells. In order to achieve this purpose, the following step-by-step 
goals were set: 
 generation of the plasmids encoding the FLAG-tagged wild-type PKACα and its two 
mutants carrying the point mutations in the amino acid residues T197 and K72; 
 control of the kinase activities and the expression levels of the PKA C proteins; 
 analysis of the replication efficiencies of HPV types 5, 11 and 18 in the presence of the 
over-expressed PKA C proteins in the U2OS cells; 
 testing the influence of potentiation or inhibition of the endogenous PKA catalytic 
activity on the replication efficiency of HPV5; 
 investigation of the possible mechanisms involved in the PKA-mediated alterations of 
the HPV18 replication. 
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2.2. Materials and methods  
2.2.1. Plasmids 
 pJET1.2/blunt vector (2974 bp) – linearized cloning vector, which is suitable for 
cloning of DNA fragments with blunt ends (CloneJET PCR Cloning Kit, Thermo Fisher 
Scientific). The vector contains multiple cloning sites (MCS), eco47IR (lethal gene, 
enables positive selection of the recombinants) and -lactamase gene containing 
resistance to ampicillin (Amp). 
 pFLAG-CMV-4 vector (6271 bp) - FLAG epitope (DYKDDDDK) containing vector 
(Sigma-Aldrich). 
 pFLAG-PKAwt – a plasmid encoding for the protein kinase A catalytic subunit α 
transcript variant 1 (PRKACA, Gene ID 5566, NCBI accession number NM_002730.4, 
referred later as PKA). The coding region of the gene was amplified using RT-PCR, 
U2OS cells derived complementary DNA (cDNA) and primers 1 and 2 (Appendix 1. 
Primers used in the study). 
 pFLAG-PKA(T197A) - a plasmid encoding the protein kinase A catalytic subunit α 
transcript variant 1 with the threonine residue at position 197 mutated to alanine.  
 pFLAG-PKA(K72R) - a plasmid encoding the protein kinase A catalytic subunit α 
transcript variant 1 with the lysine residue at position 72 mutated to arginine.  
Numbering of the mutated amino acid residues of the pFLAG-PKA(T197A) and -PKA(K72R) 
constructs is given relative to the 1st methionine of PKACα (NCBI accession number 
NP_002721.1). The mutations were introduced using PCR mutagenesis and oligonucleotides 3 
and 4 (Appendix 1. Primers used in the study). All above-mentioned PKA encoding sequences 
were cloned into pFLAG-CMV-4 vector between HindIII and NotI restriction sites. 
 pCI-GFP – a plasmid expressing Green Fluorescence Protein (GFP) (Promega, kind 
gift of Lagle Kasak, Tallinn University of Technology). 
 HPV5 minicircle (m.c.) (7756 bp) – HPV5 genome containing plasmid (Sankovski et 
al., 2014). 
 HPV11 m.c. (7931 bp) – HPV11 genome containing plasmid (Orav et al., 2013). 
 HPV18 m.c. (7893 bp) – HPV18 genome containing plasmid (Orav et al., 2013). 
 HPV5-Nluc m.c. was generated on the basis of the HPV5 wt genome by inserting the 
sequences encoding the codon optimized Nluc and the self-processed 2A region of the 
foot-and-mouth disease virus (FMDV) after the 59nd nucleotide of the E2 ORF, which 
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corresponds to the E1 stop codon. The full-length wt E2 ORF begins next to the 2A 
sequence (Piirsoo et al., 2019). 
 HPV18-Nluc m.c. was generated on the basis of the HPV18 wt genome by inserting 
the sequences encoding the codon optimized Nluc and the 2A region of the FMDV after 
the 72nd nucleotide of the E2 ORF, which corresponds to the E1 stop codon. The full-
length wt E2 ORF begins next to the 2A sequence (Piirsoo et al., 2019). 
 HPV18E1- m.c. – a plasmid encoding HPV18 wt genome containing a point mutation 
in the E1 first AUG and therefore being deficient for the E1 expression (Geimanen et 
al., 2011). 
 HPV18E8- m.c. - a plasmid encoding HPV18 wt genome containing a point mutation 
in the E8 first AUG and therefore being deficient for the E8^E2 expression (Geimanen 
et al., 2011). 
The abovementioned HPV genomes come from the laboratory collection of the Chair of 
Virology, University of Tartu. The genomes were generated as covalently closed minicircle 
plasmids in E. coli strain ZYCY10P3S2T using minicircle DNA technology and pMC.BESBX 
vector for generation of the respective parental plasmids (Kay et al., 2010; Orav et al., 2013; 
Sankovski et al., 2014). The pMC.BESBX vector contains attB and attP sites for binding of 
bacteriophage ФC31 integrase, 32 restriction sites of SceI endonuclease, MCS, kanamycin 
resistance gene, and ColE1 origin of replication.  
2.2.2 Isolation of total RNA and synthesis of cDNA 
Total RNA was isolated from U2OS cells using the Quick RNA MiniPrep Kit (Zymo Research). 
Cells were lysed in the RNA Lysis Buffer. Majority of genomic DNA was removed from the 
sample using a column containing DNA-binding resin. RNA was washed with Wash Buffer 
and eluted in DNase/RNase free water. Approximately 10 μg of the total RNA was treated with 
8 U of Turbo DNase (Thermo Fisher Scientific) for 2 h at 37 ˚C. Turbo DNase was inactivated 
by incubation at 75 ˚C for 10 min in the presence of 15 mM EDTA. The total RNA was 
precipitated with 7.5 M LiCl by centrifugation at 4 ˚ C and 15000 rpm for 15 min using MicroCL 
21R Microcentrifuge (Thermo Fisher Scientific). The samples were washed with ice-cold 75% 
ethanol and centrifuged at 4 ˚C 15000 rpm for 5 min. The pellets were resuspended in 15 μl of 
nuclease-free water.  
cDNA was synthesized using RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher 
Scientific), oligo(dT) and either 5 μg of total RNA in the case of subsequent amplification of 
the sequence encoding for PKA or 2 μg of total RNA for analysis of the HPV18 transcripts. 
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The appropriate amount of the total RNA was mixed with 1 µl of oligo(dT), incubated for 5 
min at 65 ˚C and chilled on ice. cDNA was synthesized at 45 ˚C for 1 h in total volume of 20 
μl in the presence of 4 µl of 5x Reaction Buffer, 20 U of RiboLock RNase Inhibitor, 2 μl of 10 
mM dNTP Mix and 200 U of RevertAid M-MuLV RT. The cDNA synthesis was terminated 
by heating the mix at 70 ˚C for 5 min.  
2.2.3 PCR and gel extraction of PCR products 
Reactions for qPCR were held in total 10 μl containing 0.5 μl of cDNA, 1 μM primers 5-9 
(Appendix 1. Primers used in the study) and 2 μl of 5x EvaGreen (Solis Biodyne) on MicroAmp 
96-well plates (Thermo Fisher Scientific). The qPCR was performed in triplicates using 
QuantStudio Real-Time PCR System (Thermo Fisher Scientific) and the following program: 
denaturation at 95 ˚C for 12 min, 40 cycles of amplification (denaturation 95 ˚C 15 s, annealing 
60 ˚C 15 s, synthesis 72 ˚C 15 s). 
The PKA encoding sequences were amplified using reverse transcription PCR method (RT-
PCR) and Phusion High-Fidelity DNA Polymerase Kit (Thermo Fisher Scientific). Reagents 
for the PCR included 28.5 μl of nuclease-free water, 5 μl of 10 mM dNTP mix, 10 μl of 5x 
Phusion HF or GC buffer, 1 μl of cDNA template, 0.75 μl of Phusion DNA polymerase and 1 
μM primers. Expression of the different C subunits of PKA was analyzed using primers 10-15 
(Appendix 1. Primers used in the study). Sequence encoding the PKA was amplified using 
primers 1 and 2 (Appendix 1. Primers used in the study). The constructs encoding PKA mutants 
(T197A, K72R) were generated using oligonucleotides 3 and 4 (Appendix 1. Primers used in 
the study) on the basis of the construct encoding for the PKA. 
Reaction was performed with PCR Mastercycle (Eppendorf Scientific) using the following 
program: initial denaturation of template DNA for 30 s at 98 ˚C, 32 cycles of the synthesis: 
(DNA denaturation at 98 ˚C for 8 s, annealing of the primers at 59 ˚C for 20 s, and extension at 
72 ˚C for 45 s), final extension at 72 ˚C for 5 min and cooling to 10 ˚C. The program of the 
PCR mutagenesis for generation of the sequences encoding the PKA mutants involved 20 
cycles of the synthesis with extension time 6 min. 
The PCR products were separated using the gel electrophoresis method and 0.8% agarose gel 
containing 0.3 μg of ethidium bromide in 1xTAE buffer (40 mM Tris-acetate, 1 mM EDTA) 
and in the presence of 0.6 μg of O’GeneRuler 1kb DNA ladder (Thermo Fisher Scientific). The 
required fragments were cut out from the gel with a scalpel under UV (260 nm). 
The DNA was extracted from the gel using Zymoclean™ Gel DNA Recovery Kit (Zymo 
Research) according to manufacturer`s instructions. The gel pieces with DNA were mixed with 
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ADB Buffer Gel in ratio 1:3 and incubated at 55 ˚C until the gel slices were completely 
dissolved. Melted agarose solution was transferred to the DNA-binding columns, centrifuged 
at 13000 rpm for 1 min and the flow-through was discarded. The DNA was washed two times 
with 200 μl of DNA Wash Buffer and centrifugated for 30 seconds at 13000 rpm. The column-
bound DNA was eluted in 20 μl of pure water. The DNA was additionally precipitated with 2 
μl of 5 M NaCl and 40 μl of 96% ethanol with subsequent centrifugation at 4 ˚C 15000 rpm for 
15 min. The pellets were washed with cold (−20 ˚C) 75% ethanol, centrifuged at 4 ˚C 15000 
rpm for 5 min and resuspended in 15 μl of nuclease-free water. The concentrations of nucleic 
acids were measured using a Nanodrop-1000 spectrophotometer (Thermo Fisher Scientific) at 
260 nm wavelength. 
2.2.4 Cloning of the PCR products into pJET1.2/blunt vector and transformation 
The obtained RT-PCR product was cloned into pJET1/2 cloning vector (CloneJET PCR 
Cloning Kit (Thermo Fisher Scientific)) between HindIII and NotI restriction sites. Reagents 
for the reactions included 4 μl of 5x Reaction Buffer, 350 ng of the gel-purified PCR product, 
9 U of T4 DNA Ligase and 35 μg of pJET1.2/blunt vector. The reactions were incubated at 
room temperature (RT) for 3 h.  
Competent cells of nonpathogenic E. coli strain DH5α were used for the transformation. The 
bacteria were thawed on ice for 20 min. Ligation mixes were added to 200 μl of the competent 
cells and incubated on ice for 30 min. After that, the reaction mixes were incubated at 37 ˚C for 
4 min and then transferred on ice for 1 min. Next, 800 μl of LB broth (10 g/L tryptone, 5 g/L 
yeast extract, 10 g/L NaCl) was added to each tube, and mixes were incubated at 37 ˚C for 40 
min. The tubes were centrifuged at RT and 5000 rpm for 3 min. The pellet was resuspended in 
100 μl of LB broth and plated using the spread plate technique on the LB agar supplemented 
with 50 μg/ml of Amp. The plates were incubated at 37 ˚C for 24 h. The growth of colonies 
was observed.  
The presence of the insert in the cloning vector was verified using the colony PCR method. The 
reaction mix consisted of 2 μl of 5x HOT FIREPol PCR mix (Solis BioDyne), 6.5 μl of nuclease-
free water and 1 μM of primers 1 and 2 (Appendix 1. Primers used in the study). Bacteria from 
each separate colony were transferred to the LB agar supplemented with Amp and then into the 
PCR mix using pipette tips. 
Reaction was performed using PCR Mastercycle (Eppendorf Scientific) according to the 
following program: the polymerase activation at 96 ˚C for 12 min 30 s, 25 cycles of the 
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synthesis: (denaturation at 96 ˚C for 15 s, annealing of the primers at 59 ˚C for 15 s and 
extension at 72 ˚C for 45 s).  
The obtained PCR products were analyzed on 1.2% agarose gel as described in 2.2.3. The 
correct colonies were transferred from the plates to 3 ml of LB broth containing 200 μg/ml of 
Amp and incubated at 37 ˚C and 220 rpm for 18 h in Orbital Incubator MIR-220RU (Sanyo). 
2.2.5 Plasmid DNA extraction and control with restriction and sequencing 
Plasmid DNA was extracted from bacteria using Plasmid Extraction Mini Kit (Flavoprep) or 
using Endotoxin-free Plasmid DNA Purification Midi Kit (Thermo Fisher Scientific) according 
to manufacturers’ protocol and using 3 ml or 200 ml of bacteria culture, respectively. All 
procedures were performed at RT. First, bacteria culture was centrifuged at 5000 rpm for 5 min 
and the supernatant was removed. The pellet was resuspended in the appropriate buffer (FAPD1 
or RES-EF) containing RNase A and lysed in the respective lysis buffer (FAPD2 or LYS-EF) 
for 5 min. Reactions were neutralized with FAPD3 or NEU-EF buffers, respectively, and 
centrifuged at 13000 rpm for 5 min. Supernatant containing DNA was transferred to the DNA-
binding columns. Beforehand, the NucleoBond Xtra Column (Midi kit) was equilibrated with 
EQU-EF Buffer. The column-bound DNA was washed with the appropriate washing buffers, 
eluted either with nuclease-free water or ELU-EF buffer (Midi kit). Next, the DNA extracted 
using Midi kit was precipitated with 3 ml of isopropanol, washed with 75% ethanol and 
dissolved in 1 ml of nuclease-free water. 
The obtained constructs were verified by restriction analysis using restriction endonucleases 
HindIII and BamHI (Thermo Fisher Scientific) with subsequent sequencing of the correct 
clones using pJET1/2 primers 16 (Appendix 1. Primers used in the study). For each restriction 
reaction, the following components were used: 0.5 μl of each restriction enzyme (10 U/μl), 400 
ng of each DNA sample and 2 μl of 10x FastDigest green Buffer. Total volume of a reaction 
was 20 μl. The restriction reactions were incubated at 37 ˚C for 1 h. The DNA was visualized 
under UV (260 nm) using the gel electrophoresis method as described in section 2.2.3. 
DNA sequencing was performed in Estonian Institute of Genomics Core Facility, Tartu, 
Estonia.  
2.2.6 Generation of the pFLAG-PKA constructs  
The coding sequences the PKAwt and its mutants were excised from pJET1.2/blunt vector using 
HindIII and NotI restriction enzymes, purified from agarose gel and ligated with the pre-cleaved 
with the same enzymes and gel-purified pFLAG-CMV-4 vector. The ligation reactions 
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containing 70 ng of the pFLAG-CMV-4 vector, 500 ng of the gel-purified PCR product, 1.2 μl 
of 10x reaction Buffer and 1.2 μl of T4 DNA Ligase were incubated at 16 ˚C overnight. The 
ligation mixes were transformed to competent DH5α as described in section 2.2.4. 
2.2.7 Cell culture and transfection 
The human osteosarcoma cell line U2OS were propagated in the normal growth medium 
(NGM): Iscove’s Modified Dulbecco’s Medium (IMDM, Pan Biotech), 10% fetal calf serum 
(FCS) and 1% penicillin/streptomycin (PEST, Sigma-Aldrich). A derivative of human 
embryonic kidney cell line HEK293 - 293T cells were maintained in the NGM containing 
Dulbecco’s Modified Eagle Medium (DMEM, Pan Biotech), 10% FCS and 1% PEST. The cells 
were propagated in incubator at 37 ˚C and 5% CO2.  
U2OS cells were transfected by electroporation using approximately 106 cells for each 
transfection. Confluent U2OS cells were subcultured on 10 cm cell culture dishes (Corning Inc) 
approximately 24 h before transfection. Prior electroporation, NGM was removed; the cells 
were washed with PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and 1.47 mM KH2PO4) 
and detached using 0.25% Trypsin-EDTA (Sigma-Aldrich). The detached cells were transferred 
into 8 ml of fresh NGM, centrifuged at 1000 rpm and RT for 5 min using Eppendorf Centrifuge 
5810R (Thermo Fisher Scientific) and then resuspended in the fresh NGM using 250 μl of 
medium per one transfection. Approximately 106 U2OS cells were mixed with 50 μg of salmon 
sperm DNA and the following amounts of the HPV genomes and PKA encoding plasmids: 
HPV5 and HPV5-Nluc (1500 ng), HPV11 (750 ng), HPV18, HPV18E1-, HPV18E8- and 
HPV18-Nluc (1000 ng), pFLAG-PKAwt (240 ng), pFLAG-PKA(T197A) (1000 ng), pFLAG-
PKA(K72R) (1500 ng). Transfection mixtures containing pFLAG-PKAwt and mutant pFLAG-
PKA(T197A) were compensated up to 1500 ng with the respective amounts of the pFLAG-
CMV-4 vector. Suspension of the cells with DNA was transferred into an electroporation 
cuvette with gap size of 4 mm. The electroporation was performed using a Gene Pulser XCell 
machine (Bio-Rad Instruments) at 220 V and 975 μF. After electroporation, approximately 260 
μl of NGM was immediately added to the cells. The transfected cell suspensions and NGM 
were transferred to appropriate plates. The cells were incubated for 2, 3 and 4 days. For the 
experiment with IBMX and H89 (both purchased from Sigma-Aldrich), the cells were incubated 
for 2 or 3 days after transfection and then treated with 500 μM IBMX or 5 μM H89 for 2 days 
in NGM. The NGM containing IBMX, H89 or DMSO (used as a vehicle in dilution 1:1000), 
was replenished every 24 h. 
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The 293T cells were transfected with using polyethyleneimine (PEI) (Inbio). The cells were 
plated on 10 cm cell culture dishes approximately 24 h prior transfection. Different amounts of 
the PKA encoding constructs were used for transfection of 293T cells: pFLAG-PKAwt (2500 
ng), pFLAG-PKA(T197A) (8000 ng), pFLAG-PKA(K72R) (16000 ng per two plates) and pCI-
GFP (8000 ng) for control. Transfection mixture containing pFLAG-PKAwt was compensated 
with 6500 ng of the pFLAG-CMV-4 vector. PEI stock solution was diluted in sterile water to 
final concentration 1 mg/ml and mixed with DNA in ratio 3:1 in 100 μl of pure DMEM. The 
mixture was incubated for 5-10 min at RT. The cells were washed with PBS, and 8 ml of pure 
DMEM and DNA/PEI complexes were added to the cells followed by incubation for 
approximately 2 h. Afterwards, 12 ml of NGM was added to the cells, and the cells were 
incubated for 48 h.  
2.2.8 Isolation of total DNA from U2OS cells 
U2OS cells were washed with PBS and lysed in 500 μl of Sol IV buffer (20 mM Tris pH 8.0, 
100 mM NaCl, 0.1 g/L mM EDTA, 0.2% SDS). The lysates were homogenized using insulin 
syringe and 24G needle and incubated in the presence of 200 μg/ml of Proteinase K at 56 ˚C 
overnight. Next, 500 μl of phenol-chloroform mixture (1:1) was added to each lysate. The 
samples were mixed by vortexing for 10-15 s and centrifuged at RT and 13000 rpm for 3 min. 
Upper phase containing DNA was transferred to a new microtube. Two volumes of 96% ethanol 
were added to each tube for DNA precipitation. The samples were centrifuged at 4 ˚C 15000 
rpm for 15 min using MicroCL 21R Microcentrifuge (Thermo Fisher Scientific). Supernatant 
was removed, and dry precipitate was resuspended in 100 μl of TE (10 mM Tris, 1 mM EDTA 
pH 8.0) containing 40 ng of RNase A. The mixtures were incubated at 37 ˚ C for 1 h. Total DNA 
was additionally precipitated using 10 μl of 5 M NaCl and 200 μl of 96% ethanol as described 
in 2.2.3 and resuspended in 30 μl of nuclease-free water. 
2.2.9 Luciferase assay 
U2OS cells were washed with PBS solution and lysed in 40 μl of Passive Lysis Buffer 
(Promega) for 10 min at RT. The lysates were transferred in two replicates to different 96-well 
plates for analysis of Nluc and alkaline phosphatase (AP) activities. Nluc activity was measured 
using Nano-Glo Luciferase Assay System Kit (Promega) and 20 μl of the furimazine substrate 
diluted with the Luciferase Assay Buffer in ratio 1:300. AP was measured by adding 20 μl of 
CSPD substrate (Applied Biosystems, Tropix) to 10 μl of the lysates with further incubation for 
10 min. Chemiluminescence of both substrates was measured using GloMax 96 Microplate 
Luminometer (Promega). For each sample, Nluc activity was normalized by AP activity. 
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2.2.10 Southern blot and hybridization 
The following amounts of the total DNA were used for analysis of different HPV replication 
efficiencies: 6 μg for HPV5, 3 μg for HPV11, and 5 μg for HPV18. The total DNA was digested 
with 0.8 μl of DpnI enzyme to cut the palindromic sequence (5’-Gm6A^TC-3’) of the bacterially 
methylated input DNA and 1.5 μl of SacI, HindIII and BglI enzymes (Thermo Fisher Scientific) 
to linearize the HPV5, HPV11 and HPV18 genomes, respectively. Reactions were held in total 
volume 30 μl in the presence of 3 μl of 10x FastDigest Green Buffer per one reaction at 37 ˚C 
overnight. The DNA fragments produced during the restriction reaction were separated on 0.8% 
agarose gel. 
Afterwards, the gel was incubated in Solution A (0.5 M NaOH, 1.5 M NaCl) at RT for 40 min, 
washed with distilled water and neutralized in Solution B (1 M Tris pH 8.0, 1.5 M NaCl) at RT 
for 30 min. The DNA was transferred from the gel to a nylon membrane (Millipore) using 
upward capillary transfer method in 10x saline-sodium citrate buffer (10x SSC: 1.5 M NaCl, 
150 mM Na3C6H5O7) for 18 h. 
After transfer, DNA was cross-linked to the membrane using UV light (Stratalinker). In order 
to prevent nonspecific binding, the membranes were incubated in prehybridization solution at 
67 ˚C for 45 min in rolling tubes. Prehybridization solution for one membrane consisted of 16 
ml of water, 9 ml of 20x SSC, 3 ml of 50x Denhardt’s solution, 1.5 ml of 10% SDS and 6000 
μg of salmon sperm DNA denaturated at 100 ˚C. 
For synthesis of hybridization probes, 150 ng of the linearized and gel purified HPV5, HPV11 
and HPV18 m.c. DNAs and DecaLabel TM DNA Labeling Kit (Thermo Fisher Scientific) were 
used. The linearized genomes were obtained as described in section 2.2.3. For the synthesis, 10 
μl of decanucleotide primers were added to the DNA template in a total volume of 30 μl. The 
samples were incubated at 100 ˚C for 10 min and placed on ice. Then, 3 μl of mixC (mixture of 
all dNTPs except dCTP), 4 μl of α-32P-dCTP isotope (Hartman Analytics) and 1 μl of Klenow 
Fragment lacking 5’-3’ exonuclease activity were added. After incubation of the samples at 37 
˚C for 15 min, 4 μl of dNTP were added. The reaction mixtures were incubated at 37 ˚C for 
additional 15 min. Denaturation was performed at 100 ˚C for 10 min.  
Hybridization of the membranes with the radiolabeled probes was performed in the 
prehybridization solution at 67 ˚C overnight. Next day, the membranes were washed with pre-
heated washing solutions I, II and III at 67 ˚C. The wash step was repeated twice with solution 
I (10x SSC, 0.1% SDS) for 5 min each, then once with solution II (5x SSC, 0.1% SDS) for 15 
min and twice with solution III (0.5x SSC, 0.1% SDS) for 10 min. Thereafter, the membranes 
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were exposed to the X-ray film at −80 ˚C for about 10 h. The X-ray films were developed and 
fixed using AGFA Developer and Rapid Fixer solutions.  
2.2.11 Western blot and immunoprecipitation 
U2OS cells were lysed in 500 μl of RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 2 mM 
EDTA, 0.1% SDS and 0.1% Triton X-100) supplemented with protease inhibitor cocktail (PIC, 
Sigma-Aldrich) for 10 minutes on ice. The amount of total protein was measured using BCA 
Protein Assay Kit (Pierce). The working reagent (WR) was prepared by mixing Reagent A with 
Reagent B in ratio 50:1, and 40 μl of the WR was added to 4 μl of each BSA standard or a 
sample of interest in the microplate. The plate was incubated at 37 ˚C for 30 min. The 
absorbance was measured at 562 nm on an absorbance microplate reader Sunrise using 
Magellan data analysis software (Tecan). 
293T cells were lysed in 5 ml of Sigma Lysis Buffer (50 mM Tris HCl pH 7.4, 150 mM NaCl, 
1 mM EDTA, 1% Triton X-100 and PIC) on ice for 15 min. The lysates were cleared by 
centrifugation at 4 ˚C 15000 rpm for 5 min, and supernatant was transferred to the new tubes. 
The over-expressed proteins containing the FLAG epitope were precipitated using 20 μl of 
ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich), previously washed 2 times with PBS solution 
and one time with Sigma Lysis Buffer. Precipitation was carried out at 4 ˚C under slow end-to-
end rotation overnight. The immunocomplexes were washed with 2 ml of the Sigma Lysis 
buffer 3 times for 10 min and resuspended in 100 μl of PBS.  
Next, 15 μg of total proteins obtained from U2OS cells or 10 μl of immunoprecipitated proteins 
from 293T were mixed with the respective amount of 3X Laemmli Sample Buffer (0.125 M 
Tris-Cl, pH 6.8, 4% SDS, 20% glycerol, 100 μM DDT, 0.004% bromophenol blue). The 
samples were denaturated at 100 ˚C for 5 min.  
Proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to PVDF 
membrane (Millipore). The membrane was blocked in PBS solution containing 0.1% Tween-
20 (PBS-T) and 5% of non-fat dry milk for 30 min at RT. Afterwards, the membrane was 
incubated with a primary antibody at 4 ˚C overnight. The following procedures were performed 
at RT. The membrane was washed in PBS-T 3 times for 15 min, incubated with a secondary 
antibody (if appropriate) for 1 h with subsequent washing with PBS-T 3 times for 15 min. The 
following antibodies were used: Monoclonal ANTI-FLAG M2−HRP antibody (Sigma-Aldrich, 
1:3000), anti-GAPDH (Sigma-Aldrich, 1:5000) and goat anti-mouse IgG conjugated with HRP 
(Invitrogen, 1:10000). Antibodies were diluted in PBS-T solution containing 2.5% of non-fat 
dry milk. Enhanced chemiluminescence substrate for HRP (SuperSignal™ West Dura 
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Extended Duration kit, Pierce) was added to membrane for 1 min. The membrane was rinsed 
in PBS-T, exposed to X-ray film and developed as described in 2.2.10. 
2.2.12 In vitro kinase assay 
For the assay, 10x PKA kinase assay buffer (KAB) containing 400 mM Tris-HCl pH 7.5, 200 
mM MgCl2, 500 µM DTT in nuclease-free water was prepared. Solutions containing 200 µM 
“cold” ATP and 400 µM γ32-ATP in 1x KAB were made. Next, 10 µl of PKAwt and 
PKA(T197A), PKA(K72R) immunoprecipitants and bacterially purified PKA substrate Nth1 
(86 kDa, kind gift from M. Loog laboratory) were mixed in 40 µl of 1X KAB on ice.  
Ten µl of each reaction was immediately transferred to another microtube for running a separate 
SDS-PAGE gel and subsequent staining of the gel with Coomassie Brilliant Blue to visualize 
the Nth1 substrate.  
Then, 3.4 µl of the γ32-ATP solution (0.4 µl of γ32-ATP per sample) was added to the “cold” 
ATP solution, and 10 µl of the mixture was transferred to each immunocomplex. In vitro kinase 
reactions were carried out at RT for 30 min and stopped by adding the Laemmli Sample Buffer 
and incubation at 100 ˚C for 5 min. After this, the proteins were separated using SDS-PAGE 
on 12% gel. The gel was transferred to filter paper and dried using Gel Vacuum Dryer Heto 
Dry GD-2 (HETO) for 45 min at 70 ˚C. Autoradiogram of the gel was obtained using the 
cassette with intensifying screen and Typhoon FLA 9500 (GE Healthcare) after overnight 
exposure at RT. 
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2.3. Results 
2.3.1 Selection of PKA subunit 
It has been established that at least three different PKA catalytic subunits (PKA C) are encoded 
by human genome: PRKACA (NCBI accession numbers for different isoforms 
NM_001304349.1; NM_002730.4; NM_207518.3), PRKACB (NCBI accession numbers for 
different isoforms NM_001242857.2; NM_001242858.2; NM_001242859.2; 
NM_001242860.2; NM_001242861.2; NM_001242862.2; NM_001300915.2; 
NM_001300916.2; NM_001300917.2; NM_002731.3; NM_182948.4; NM_207578.3) and 
PRKACG (NCBI accession number NM_002732.3). An expression pattern of different PKA C 
was analyzed in two different human cell lines capable for supporting HPV replication: HPV31-
positive human primary keratinocytes CIN612E and osteosarcoma cell line U2OS. Expression 
of PKA C mRNAs was analyzed using RT-PCR and 2 independent pairs of primers for each 
gene (primers 10-15, Appendix 1. Primers used in the study). Also, mRNA expression of the 
house keeping gene GAPDH was analyzed as a positive control. Our analysis (Figure 5) 
revealed that PRKACA and PRKACB mRNAs were expressed in both cell lines. However, 
expression of PRKACG mRNA was detected only in U2OS cells using one pair of primers. 
Therefore, feasibility of the PRKACG-encoded protein to be involved in regulation of HPV 
replication proteins was considered as insignificant. 
Bioinformatic analysis of the PKA C proteins was performed using NCBI blast algorithm. 
PKACα and PKACβ proteins were approximately 92% identical, while PKACα and PKACγ 
had 84% identity; PKACβ and PKACγ had approximately 79% identity. Between the two 
isoforms, PKACα was chosen for further research because of its evident expression level in the 
target cells and high identity percent with PKACβ protein, suggesting possible similarity of the 
biological activities of these proteins. 
Next, the sequence of the PRKACA transcript variant 1 (NCBI accession number 
NM_002730.4) encoding the PKACα1 protein (NCBI accession number NP_002721, further 
referred as PKAwt) was amplified using RT-PCR and primers 1-2 (Appendix 1. Primers used 
in the study) and cloned into the pFLAG-CMV-4 vector. The resulted construct is further 
referred as pFLAG-PKAwt. On the basis of the pFLAG-PKAwt construct, the constructs 
encoding PKACα mutants (referred as pFLAG-PKA(T197A) and pFLAG-PKA(K72R)) were 
generated using PCR mutagenesis. 
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Figure 5. RT-PCR analysis of the expression of PKA C in CIN612E and U2OS cells. Expression of the 
housekeeping gene GAPDH was analyzed as a positive control. (1) CIN612E cDNA; (2) U2OS cDNA; (3) 
CIN612E-RT*; (4) U2OS-RT*. Probes (3) and (4) were identical to the samples (1) and (2), respectively, but they 
did not contain reverse transcriptase (RT) during cDNA synthesis; these samples were analyzed to confirm absence 
of contamination with genomic DNA. To estimate the size of the obtained PCR products, O’GeneRuler 1kb DNA 
ladder was used. 
2.3.2 Control of expression level of PKA C proteins in U2OS cells 
It has been suggested that the proteins can be stabilized through (auto)phosphorylation 
processes, which may influence their expression levels and biological activity in cells. 
Therefore, immunoblotting analysis was required to determine the amounts of the PKA-
encoding constructs expressing similar levels of the wt and mutant PKA C proteins in the U2OS 
cells in order to further compare their biological effects.  
Approximately 106 U2OS cells were transfected with different amounts of the generated 
PKACα-encoding constructs. Expression levels of the PKAwt and PKA(T197A), PKA(K72R) 
were analyzed 48 h post-transfection using Western blot (WB) and Monoclonal ANTI-FLAG 
M2−HRP antibody. Eventually, the following ratio of the constructs were found to be optimal 
to produce similar levels of the wt and mutant PKA C proteins: pFLAG-PKAwt 240 ng, 
pFLAG-PKA(T197A) 1000 ng, and pFLAG-PKA(K72R) 1500 ng (Figure 6, upper panel). The 
total amount of the transfected DNA was compensated with the respective amount of the empty 
vector to achieve similar transfection conditions. Amount of total protein was measured prior 
to SDS-PAGE to ensure the equal loading of the lysates, which was additionally controlled via 
immunoblotting analysis of the housekeeping protein GAPDH (Figure 6, lower panel). The WB 
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showed that the generated constructs encoded approximately 42 kDa proteins. Also, the analysis 
revealed that the levels of PKAwt and mutant proteins expressed using the indicated amounts 
of the plasmids were similar. Therefore, this ratio of the PKA-encoding plasmids was used in 
the further experiments.  
 
Figure 6. Over-expression studies of the FLAG-tagged proteins PKAwt, PKA(T197A), and PKA(K72R). U2OS 
cells were transfected with the following amounts of the plasmids: 240 ng pFLAG-PKAwt, 1000 ng pFLAG-
PKA(T197A), 1500 ng pFLAG-PKA(K72R) and 1500 ng pFLAG-CMV-4 vector as a negative control. The cells 
were incubated for 2 days, lysed and subjected to immunoblotting assay. Detection of FLAG-tagged proteins was 
made using ANTI-FLAG antibody. GAPDH was analyzed as a loading control and detected with anti-GAPDH 
and goat anti-mouse IgG conjugated with HRP antibodies. 
2.3.3 Control of kinase activity of the subunits encoded by the pFLAG-PKA constructs  
The mutated PKACα subunits encoded by the generated pFLAG-PKA(T197A) and pFLAG-
PKA(K72R) constructs should have severely reduced catalytic activity in contrast to pFLAG-
PKAwt. Mutation of T197 to alanine (referred as dephosphorylated mutant) was previously 
shown to reduce PKA catalytic function, suggesting that the hydroxyl group of the threonine 
residue may play a significant role in stabilizing the active site and promoting the phosphoryl 
transfer reaction (Adams et al., 1995; Cheng et al., 2006). Mutation of K72 to arginine with so-
called “bulkier residue”, prevents the catalytic cleft from assuming its proper conformation 
needed for the kinase activity (Iyer et al., 2005). In vitro kinase assay with γ32-ATP was 
performed in order to analyze the ability of the PKAwt and mutant subunits to catalyze the 
phosphorylation reaction.  
In order to obtain the target FLAG-tagged proteins, 293T cells were transfected with pFLAG-
PKAwt (2500 ng), pFLAG-PKA(T197A) (8000 ng), pFLAG-PKA(K72R) (16000 ng per two 
10 cm plates) and pCI-GFP (8000 ng) for negative control. Proteins PKAwt, PKA(T197A), and 
PKA(K72R) were immunoprecipitated 48 h after the transfection and used for subsequent in 
vitro kinase assay and immunoblotting. The first set of the kinase reactions contained only the 
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target PKA C proteins. The second set of the reaction mixes (lanes 5-8) contained also the Nth1 
protein (86 kDa) - one of the substrates for PKA. The kinase assay reactions were loaded on 
two separate acrylamide gels. One of the gels was exposed to phosphor imager to detect the 
radioactive signals (Figure 7, upper panel). Another gel was stained with Coomassie Brilliant 
Blue to visualize the Nht1 protein (Figure 7, lower panel).  
The results of the assay demonstrate that, in contrast to the PKAwt, both PKA(T197A) and 
PKA(K72R) have hardly visible residual catalytic activity: very faint signals of Nth1 
phosphorylation were detected. Therefore, the PKA C mutants can be considered as “kinase-
dead” ones. These data ensure that the effects observed using these mutant proteins are 
associated with their inability to catalyze the phosphorylation reaction. Besides, only PKAwt 
was able to phosphorylate itself generating a radioactive signal at approximately 42 kDa that 
corresponds to the molecular mass of the PKA C (Figure 6). 
 
Figure 7. In vitro kinase activity of FLAG-tagged proteins PKAwt, PKA(T197A), and PKA(K72R). The proteins 
were immunoprecipitated 48 h after the transfection of 293T cells and subjected to in vitro kinase assay (upper 
panel). The bottom panel depicts the PKA substrate Nth1 stained with Coomassie Brilliant Blue. Bands marked 
with an asterisk show an unknown substrate phosphorylated by PKAwt in the cell lysate. 
2.3.4 Effects of the over-expressed PKA C proteins on the replication of HPV5, HPV11, 
HPV18 
The association between the phosphorylation activity of kinases and the replication of different 
HPV types has been previously established. Catalytic activity of CK2 subunit is required for 
the stability of E1 regulatory protein of HPV11 and 18, while MAPKs, CDKs, FGFR3 kinases 
play an important role in E1 and E2 nuclear localization of different HPV types, thereby 
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participating in regulation of the viral genome replication (Deng et al., 2004; Ma et al., 1999; 
Piirsoo et al., 2019; Xie et al., 2017; Yu et al., 2007). Considering that several HPV proteins 
contain putative phosphorylation sites for PKA, it has been hypothesized that PKA activity 
influences the replication efficiency of different HPV types. 
In order to examine this hypothesis, the U2OS cells were transfected with wild type HPV 
genomes (LR β type HPV5, LR α type HPV11 and HR α type HPV18), pFLAG-PKA constructs 
in the optimal concentrations, as described above, and pFLAG-CMV-4 vector as a control. 
Total DNA was isolated 48 h, 72 h and 96 h after the transfection and treated with the respective 
linearizing restriction enzyme (SacI for HPV5, HindIII for HPV11, and BglI for HPV18) and 
DpnI for the digestion of the input HPV DNA purified from bacteria. The DNA was 
subsequently analyzed using southern blot (SB). All the experiments were repeated three times. 
Data of representative experiments are shown in Figure 8 for HPV5 (A), HPV11 (B) and 
HPV18 (C). SB signals of three independent experiments were quantified using GelQuantNet 
program. The signals obtained in the samples transfected with the respective genome and empty 
vector and incubated for 48 h were set as 100%. Data for other samples were calculated relative 
to the control (Figure 8A-C, right panels). 
Eight kb bands detected on the autoradiograms correspond to the replicated HPV5, HPV11 and 
HPV18 DNA. Over-expression of PKAwt was accompanied with strong (approximately 29-
fold) reduction of HPV5 replication (Figure 8A, lanes 4-6). In contrast to PKAwt, the mutant 
PKA C proteins demonstrated reduced ability to down-regulate HPV5 replication, 
approximately 1.5- and 3-fold for PKA(T197A) and PKA(K72R), respectively (Figure 8A, 
lanes 7-12). These data suggest that PKA down-regulates HPV5 replication in a kinase activity-
dependent manner. Results of HPV18 replication assay were the opposite to the ones observed 
with HPV5: over-expression of PKAwt resulted in increased HPV18 DNA amount, more than 
12-fold in 48 h and up to 3-fold in 72 h (Figure 8B, compare lanes 1-3 and 4-6). Quantification 
showed that replication signal of HPV18 in the presence of PKAwt reached its maximum level 
in 48 h and did not change substantially during the prolonged incubation (Figure 8B, right 
panel). Compared to “kinase-dead” mutants (Figure 8B, lanes 7-12), it is clearly visible that 
any impairment in PKA catalytic activity eventuated in reduced ability of HPV18 for 
replication.  
The results in Figure 8C, otherwise, showed only slight increase in the amount of the replicated 
HPV11 DNA in the presence of the over-expressed kinase-competent or kinase-deficient PKA 
C proteins. These data indicate that in contrast to HPV5 and HPV18, HPV11 replication cycle 
was not extensively affected by PKA kinase activity. Therefore, study of HPV11 replication 
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was excluded from the further research. The obtained results demonstrate that PKA activity 
influences differently the replication efficiency of different HPV types.  
 
Figure 8. Replication signal of HPV types 5, 18, 11 in the U2OS cells transfected with 1500 ng pFLAG-CMV-4 
vector, 240 ng pFLAG-PKAwt, 1000 ng pFLAG-PKA(T197A), 1500 ng pFLAG-PKA(K72R) constructs. Total 
DNA was extracted 48 h, 72 h and 96 h after the transfection, treated with restriction enzymes DpnI and 
SacI/BglI/HindIII linearizing HPV5, HPV18 and HPV11 genomes, respectively, and subjected to SB. Quantified 
signals are shown in the right panels. The signal of the control sample transfected with HPV genome and empty 
vector and extracted at 48 h was set as 100%. Data from other samples are shown as a percentage of the control 
(the average mean +/- SD (n=3)). A: co-transfection with 1500 ng of HPV5; B: co-transfection with 1000 ng of 
HPV18; C: co-transfection with 750 ng of HPV11. 
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2.3.5 IBMX, H89 and over-expressed pFLAG-PKAwt construct effects on HPV5 
replication 
The results of our over-expression experiments showed that HPV5 replication was inhibited in 
the presence of PKAwt. However, it was restored to some extent when PKA(T197A) and 
PKA(K72R) were added instead of PKAwt. These data suggest that PKA regulates HPV5 
replication in a kinase activity-dependent manner. PKA activity can be regulated by special 
agents, which can affect the enzyme activity or the function of other essential compounds of 
the PKA-activating signaling cascade. One of the PKA activators is IBMX, which increases 
cellular cAMP levels by inhibiting PDE activity (Chen et al., 1998). H89 is an inhibitor of PKA, 
competitive for ATP binding site on the C subunit, and thereby preventing phosphorylation 
reaction of target proteins (Murray, 2008). In order to support our findings, it was decided to 
conduct bioluminescent reporter assay with subsequent SB analysis to test the effects of IBMX 
and H89 on the replication of the HPV5-Nluc genome. 
For the first part of the experiment, U2OS cells were transfected with the HPV5-Nluc genome, 
pFLAG-CMV-4 empty vector and the pFLAG-PKA constructs. Next day, H89 or DMSO were 
added to the cells. For the second part of the experiment, U2OS cells were transfected with the 
HPV5-Nluc plasmid only and treated with IBMX, H89 and DMSO (as a negative control). The 
cells were incubated for 3 days and analyzed using Nluc assay and SB. It has been established 
that the amount of emitted light is proportional to Nluc gene expression levels and also it 
correlates well with HPV5-Nluc copy number in cells. Nluc activity was normalized to AP 
levels in order to correct for probable variations caused by factors such as possible toxicity of 
the used chemicals resulting in reduced amount of the treated cells. For SB assay, 5 μg of total 
DNA was linearized with SacI and treated with DpnI. Filter with the transferred from agarose 
gel DNA was hybridized with the radioactively labelled HPV5 probe and exposed to the X-ray 
film. The experiment was repeated twice. 
The results from the first part of the experiment are shown in Figure 9A. Over-expression of 
PKAwt suppressed HPV5-Nluc genome replication more than 90%, while PKA(T197A) and 
PKA(K72R) were less efficient inhibiting HPV5-Nluc replication approximately 50% probably 
due to their residual catalytic activity. Interestingly, H89 slightly stimulated the replication of 
HPV5-Nluc inhibited by the mutant PKA C proteins but could not overcome the influence of 
the over-expressed catalytically active PKA C protein. However, inhibition of the endogenous 
PKA catalytic activity with H89 resulted in increased HPV5-NLuc replication (Figure 9A, 
column 1 and 2). Generally, the levels of the normalized Nluc activity correlated with the results 
obtained using HPV5 genome and SB assay (Figure 8A). 
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The second part of the experiment allowed to evaluate the influence of the endogenous PKA 
activity on HPV5-Nluc replication efficiency. The results of Nluc assay showed approximately 
2-fold decrease in HPV5-Nluc copy number, when endogenous PKA catalytic activity was 
potentiated with IBMX (Figure 9B). In contrast, endogenous PKA activity inhibition with H89 
resulted in increased replication of the viral genome. These results demonstrate that the absence 
of active PKA benefits successful HPV5 replication. 
In order to additionally check, if Nluc activity measurements correlate with the replicated HPV5 
DNA amount in cells, SB analysis was conducted. The obtained SB results are entirely 
congruent with Nluc assay findings (Figure 9C). 
 
Figure 9. Replication signal of HPV5-Nluc. U2OS cells were transfected with HPV5-Nluc genome and pFLAG-
CMV-4 vector, pFLAG-PKA, pFLAG-PKA(T197A), or pFLAG-PKA(K72R) constructs, if indicated. Next day 
after transfection, the cells were treated with DMSO, 5 μM H89 or 500 μM IBMX. The treatment was repeated 
every day. The cells were incubated for 3 days.  
A, B: Nluc activity was measured in triplicates and normalized to AP phosphatase activity. Normalized Nluc 
activity of the control cells was set as 100%, and the data of other samples are presented as percentage of the 
control (the average mean +/- SD (n=2)). RLU: relative luminescence unit.  
C: DNA was extracted, linearized with SacI and treated with DpnI. Pictures were captured with short and long 
exposure time to better distinguish the differences in the signals. 
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The results obtained in these experiments suggest that both treatments, either activation of 
endogenous PKA with IBMX or PKAwt over-expression, inhibited HPV5 genome replication 
in U2OS cells, which can be observed as decreased Nluc signals or decreased replicated HPV5 
DNA amount. It can be concluded that PKA kinase activity regulates negatively HPV5 
replication. Taken together, our data suggest the PKA activators as a potential tool for 
modulating HPV5 infection.  
2.3.6 Mechanism of activation of HPV18 replication in response to over-expression of 
PKAwt protein 
It is known that HPV itself encodes protein for the repression of viral replication, such as 
regulatory protein E2 and its truncated form E8^E2, which is a powerful transcriptional 
repressor, with even stronger repressive effect than E2-TA protein (Stubenrauch et al., 2000). 
Taking into account the data of the previous studies showing that some cellular kinases are able 
to regulate the viral replication process and the results of our SB assay showing the increase in 
the amount of HPV18 DNA in U2OS cells in response to PKAwt over-expression, one of the 
possible mechanisms of the over-expressed PKAwt-mediated activation of HPV18 replication 
could be linked to a down-regulation of E8^E2 transcript. 
To test this hypothesis, it was essential to analyze the level of the viral transcripts synthesized 
in response to over-expressed PKA C proteins. U2OS cells were transfected with the 
appropriate amount of pFLAG-CMV-4 vector, pFLAG-PKA constructs and the HPV18E1- 
genome. Due to deficiency of the E1 expression, HPV18E1- genome is transcriptionally active 
but not able to replicate and produce replicons that can later interfere with RT-PCR. In 48 h 
after the transfection, total RNA was extracted, treated with Turbo DNase and used for cDNA 
synthesis. The quantitative RT-PCR (qPCR) was performed using primers 6-9 (Appendix 1. 
Primers used in the study). The mRNA expression levels of the viral E1, E2, E1^E4 and E2^E8 
transcripts were analyzed in triplicates and normalized to GAPDH mRNA expression levels 
measured using primers 5 (Appendix 1. Primers used in the study). The experiment was 
repeated two times. 
The results of qPCR are shown in Figure 10. Expression levels of the transcripts encoding the 
full-length viral replication proteins E1 and E2 remained similar to the control in all samples. 
In addition, the amount of E1^E4 - alternative transcript shown to be essential for effective 
amplification of viral DNA (Davy et al., 2002; Doorbar et al., 1991) is increased in the presence 
of the over-expressed PKAwt. In addition, the amount of E8^E2 transcript decreased more than 
95%, while PKAwt was over-expressed. It can be concluded that PKA activity may influence 
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the splicing, stability or production of E8^E2 transcript, which encodes the powerful 
transcriptional repressor, and the lack of the E8^E2 repressor results in increased HPV18 
replication. 
 
Figure 10. HPV18 transcripts synthesized in 48 h in U2OS cells. U2OS cells were transfected with HPV18E1- 
genome and pFLAG-CMV-4 vector, pFLAG-PKAwt and pFLAG-PKA(K72R) plasmids. Total RNA was 
extracted, and cDNA was synthesized. Expression levels of HPV18E1- transcripts were analyzed using qPCR in 
triplicates and normalized to GAPDH mRNA expression levels. Expression level of each transcript was set as 1 in 
the control cells transfected with the empty vector, and the data from other samples were calculated relative to the 
control. The data are presented as the average mean +/- SD of two independent experiments.  
To test, whether the reason for the increased HPV18 replication in response to PKAwt over-
expression is only due to down-regulation of the E8^E2 transcripts or it is a combined effect of 
some independent mechanisms, the replication efficiency of HPV18E8- genome in the presence 
or absence of over-expressed PKAwt was analyzed and compared with that of the HPV18 
genome. U2OS cells were transfected with different amounts of HPV18 or HPV18E8- 
minicircles (250 and 400 ng) and pFLAG-PKAwt plasmid or empty vector. The HPV18E8- 
genome contains a point mutation in the E8^E2 ATG and therefore it is deficient for E8^E2 
expression and allows to monitor the viral replication in the absence of E8^E2 repressor. Total 
DNA was extracted from U2OS cells 3 d after the transfection, linearized with BglI, treated 
with DpnI restriction enzymes and subjected to SB analysis (Figure 11A). The SB signals were 
quantified (Figure 11B). The experiment was repeated twice. 
The obtained results showed that PKAwt over-expression up-regulated the HPV18 replication 
approximately 22-fold. HPV18E8- replication signal was approximately 30-fold higher than 
that of HPV18. Interestingly, PKAwt over-expression was able to enhance HPV18E8- genome 
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replication, but only 1.5-fold. Taken together, it can be concluded that PKA activity may be 
involved in positive regulation of HPV18 replication because it decreases the amount of E8^E2 
transcript. However, it appears to be a mixed-type mechanism because of additional PKA-
mediated positive effect on HPV18E8- replication. Further research is needed for the better 
understanding of the PKA-mediated regulation of HPV18 replication. 
 
Figure 11. A: Replication signal of the HPV18 and HPV18E8- in the U2OS cells transfected with 250 and 400 ng 
of HPV18 or HPV18E8- genomes, pFLAG-CMV-4 vector or pFLAG-PKAwt construct. DNA was extracted 3 d 
after the transfection, linearized with BglI and treated with DpnI, and analyzed using SB.  
B: SB signals shown in the panel A were quantified. The signal of the control sample transfected with HPV18 and 
empty vector was set as 100%. Data from other samples are shown as a percentage of the control. 
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2.4. Discussion 
HPV infections cause approximately 600000 cases of cervical, vulvar, vaginal, penile, anal and 
oropharyngeal cancers every year, as well as benign diseases such as genital warts (Arbyn et 
al., 2012). HPV infections are strongly associated with sexual transmission but the nonsexual 
modes (e.g. skin-to-skin contacts) are also common (Sun‐Kuie et al., 1990). The connection 
between host cell protein kinases and HPV life cycle has been previously demonstrated (Piirsoo 
et al., 2019; Sekhar and McBride, 2012; Xie et al., 2017). It was shown that phosphorylation 
may influence viral replication both negatively and positively. An ubiquitously expressed 
kinase PKA has many targets for phosphorylation. Bioinformatic analysis suggests that 
replication proteins E1 and E2 of different HPV types has several putative PKA consensus sites 
R-R/K-X-S/T (Kennelly and Krebs, 1991). These data suggest that PKA can affect activity of 
viral proteins and participate in regulation of HPV replication. The characterization of potential 
association between PKA and HPV proteins may help to learn more about the regulation of the 
HPV life cycle in host cells and give a clue for developing new drugs against HPV infections. 
Uncovering the correlation between PKA activity and viral replication, and particularly, 
understanding if there is any HPV type-specificity, can help to get deeper insight of replication 
strategies of LR and HR HPVs.  
The research of viral replication generally requires sophisticated, expensive and time-
consuming methods; therefore, obtaining that kind of information is complicated. This study 
uses the advantages of easily cultured U2OS cells that support replication of many HPV types 
(Geimanen et al., 2011). In the present study, we have found that two different PKA C, 
PRKACA and PRKACB, are expressed in the U2OS cells as well as in HPV31-positive human 
keratinocytes. Since the proteins encoded by these genes share very high rate of homology 
(92%) that suggest their functional similarity, only one of them, PKACα, has been chosen for 
further experiments.  
This study introduces plasmids, to express FLAG-tagged PKACα wild type and its two 
catalytically deficient mutants (T197A, K72R), and compares the influence of their over-
expression on replication levels of different HPV types. The following HPVs have been chosen 
for analysis: HPV5 as an oncogenic β HPV associated with different types of skin cancers, 
HPV11 as one the most frequent LR α-HPVs responsible for development of genital warts, and 
HPV18 as a widespread oncogenic or HR α-HPV associated with cancers of mucosal epithelia. 
As a result, the replication of HPV5 and HPV18 was found to be PKA-dependent, while the 
HPV11 replication was found to be independent of PKA activity in U2OS cells. HPV5 
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replication level was severely decreased, while PKAwt was over-expressed or endogenous 
PKA activity was potentiated with PKA activator IBMX. We have also described that 
suppression of PKA activity with H89 resulted in increased level of the HPV5 replication. 
Therefore, PKA activators and inhibitors can be considered as a possible tool for the regulation 
of the HPV5 replication.  
According to Sekhar and McBride (Sekhar and McBride, 2012), PKA may be a positive 
regulator of the HPV8 E2 protein phosphorylating it in the highly conserved serine residue at 
position 253 (S253). HPV8 and HPV5 both belong to β genus and, according to the Multiple 
Sequence Alignment, both have conserved R-XX-S kinase motif with the serine in 253rd 
position. Therefore, the results of this article somewhat contradict our findings. HPV8 E2 
protein has increased half-life due to the phosphorylated S253. This phosphorylation also 
promotes partition of the viral genome to daughter cells due to more efficient binding of the 
phosphorylated E2 (S253) to cellular chromatin. However, the authors failed to demonstrate 
convincingly that this phosphorylation is mediated by PKA because of the presence of some 
residual amount of the phosphorylated E2 in the CV-1 cells treated with PKA inhibitor H89. In 
addition, this study failed to find the connection between the phosphorylated S253 and HPV8 
replication, showing that S253 mutation to alanine (S253A) did not influence the ability of E2 
protein to support viral replication in U2OS cells. Therefore, although the S253 
phosphorylation might be crucial for regulation of E2 proteins of β HPVs, direct association of 
this phosphorylation with PKA and HPV replication efficiency has not been demonstrated. 
Taken together the results of both Sekhar and McBride and our study, it can be concluded that 
either another protein kinase may be responsible for the S253 phosphorylation or PKA-
mediated regulation of HPV5 and HPV8 replication differs, since PKA inhibits the HPV5 
replication. However, further studies are required to investigate the exact molecular mechanism 
of PKA-mediated suppression of the HPV5 replication. 
In contrast to HPV5, PKA catalytic activity intensifies HPV18 replication suggesting that PKA 
may be a positive regulator of the HPV18 life cycle. We have shown that up-regulation of the 
HPV18 replication in response to PKAwt over-expression is associated with decreased amount 
of the E8^E2 transcript. However, the replication of HPV18E8- mutant genome deficient for the 
E8^E2 expression was also stimulated by the over-expressed PKA, but to less extent compared 
to wt HPV18. PKA-mediated up-regulation of HPV18E8- replication suggests the involvement 
of some yet unknown additional mechanism(s) along with the observed down-regulation of the 
E8^E2 expression.  
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It can be hypothesized that PKA acts via activation of CREB-, ATF-1- or CREM-mediated 
pathway, which either inactivates or blocks the promoter p1193 required for the synthesis of 
HPV18 E8^E2 transcript. This group of transcription factors (CREB family) participate in 
activation or inhibition of their target gene expression via binding to either palindromic full 
(TGACGTCA) or half CRE (TGACG/CGTCA) sites (Montminy, 1997). The activated PKA 
phosphorylates and promotes the binding of CREB family transcription factors to the CRE 
region, which regulates the expression of its downstream targets (Sakamoto and Frank, 2009). 
There are three CRE half-sites in the HPV18 genome (PaVE accession number: gi|60975): 761 
(CGTCA), 1015 and 3440 (TGACG) nucleotides (numbering is given from the 1st 5` nucleotide 
of the CREB consensus site). The E8^E2 transcript is initiated from p1193 promoter (ranging 
1142-1319 nucleotides) and is spliced as -1357/3434 (Toots et al., 2014). One of the CRE half-
sites is located near the p1193 promoter. Binding of the CREB family transcription factors in 
the proximity of this promoter may influence it activity and somehow interfere with the 
expression of E8^E2 transcriptional repressor. 
In the HPV5 genome, there are four CRE half-sites (PaVE accession number: gi|333071): 
nucleotides 962, 1386, 3241 (TGACG) and 6588 (CGTCA) (numbering is given from the 1st 5` 
nucleotide of the CREB consensus site). One of these sites locates near the p840 promoter 
mapped to 708-915 nucleotides. It has been demonstrated that the HPV5 promoter p840 is 
involved in expression of the early genes encoding the E1 and E2 replication proteins 
(Sankovski et al., 2014). It can be hypothesized that inhibition of the HPV5 replication in 
response to the catalytically active PKA occurs because of the binding of the CREB family 
transcription factors to p840 promoter that in turn inhibits the expression of the regulatory 
proteins E1 and E2. In contrast to HPV5 and HPV18, no CRE consensus sequences have been 
found in the HPV11 genome, which can explain the observed inability of PKA to regulate the 
HPV11 replication. Also, PKA can influence HPV replication via direct phosphorylation and 
regulation of the viral E1 and E2 proteins or their interacting partners involved in regulation of 
HPV replication. However, to make these kinds of conclusions, further research is needed. 
The obtained results are important for better understanding the life cycle of different types of 
HPVs. Furthermore, it can be speculated that the PKA effects are HPV type-dependent (if PKA-
mediated effects are different in LR and HR types) or tropism-dependent (if PKA-mediated 
effects are different in mucosal and cutaneous HPVs); however, more experiments are needed 
to make this kind of conclusions. Most certainly, the long-term goal of this project is to get 
deeper insight the interactions between the host cell factors such as PKA, and different HPV 
types to develop novel strategies for effective treatment of HPV infections. 
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CONCLUSION 
The present research was focused on the ability of PKACα subunit to influence the level of 
replication of HPV5, HPV11 and HPV18. The study resulted in the following conclusions: 
 The mutant PKACα subunits carrying the point mutations in the amino acid residues 
T197 and K72 exhibit only minimal residual catalytic activity, and therefore may be 
used as a negative control for over-expression studies investigating the PKA catalytic 
activity-dependent processes. 
 IBMX-mediated stimulation of the endogenous PKA catalytic activity or over-
expression of catalytically active PKA results in strong inhibition of the HPV5 genome 
replication.  
 The replication of HPV11 is not PKA-dependent. 
 The over-expressed PKA up-regulates the HPV18 genome replication in a kinase 
activity-dependent manner.  
 PKA phosphorylation activity influences HPV18 replication using a mixed-type 
activation mechanism. We show that PKA-mediated activation of the HPV18 
replication occurs mainly due to down-regulation of the E8^E2 transcript expression 
that encodes the strong transcriptional repressor negatively regulating the HPV18 
replication.  
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Mõnede HPV tüüpide replikatsioon on moduleeritud cAMP-sõltuva proteiinkinaasi 
aktiivsuse poolt 
Olga Sahharov 
RESÜMEE 
Inimese papilloomiviirused (HPV) on kaheahelalise DNA genoomiga viirused, mis nakatavad 
basaalseid keratinotsüüte nahas või limaskestades ja levivad mikrokahjustuste kaudu. HPV 
kodeerib tüüpiliselt kuute varajast ja kahte hilist valku. Varajased valgud vastutavad viiruse 
replikatsiooni regulatsiooni ja nakatunud raku rakutsükli muutuste eest. Hilised valgud 
moodustavad kapsiidi ja vastutavad rakust väljumise eest. HPV alatüüpe jagatakse kahte 
kategooriasse vastavalt viiruse onkogeensele potentsiaalile: „madalariski“ tüübid põhjustavad 
tüükaid, „kõrge riskiga“ HPV-d tekitavad kaela-, pea-, naha- ja anogenitaalpiirkonna vähki, 
millest kõige levinum on emakakaelavähk.  
Üheks terapeutiliseks sihtmärgiks on HPV replikatsioonitsükli inhibeerimine, aga selle 
strateegia kasutamiseks on vaja lähemalt uurida molekulaarseid interaktsioone peremeesraku ja 
viiruse vahel. Proteiinkinaasid reguleerivad erinevaid bioloogilisi protsesse rakkudes, muutes 
märklaudvalkude aktiivsust. HPV E1 ja E2 regulaator-valgud sisaldavad mitut 
proteiinkinaaside konsensus saiti, sealhulgas ka proteiinkinaas A (PKA) oma. Antud 
magistritöö eesmärgiks oli teada saada, kuidas PKA katalüütiline subühik α (PKACα) mõjutab 
erinevate HPV alatüüpide replikatsiooni efektiivsust U2OS rakkudes. Valitud tüüpideks oli 
HPV5, HPV11 ja HPV18, mis kuuluvad erinevatesse klassidesse ja riskirühmadesse.  
Uurimistöö raames loodi plasmiidid, mis kodeerivad FLAG-märgisega PKACα subühikut 
(PKAwt) ja tema kahte katalüütiliselt inaktiivset mutanti (PKA(T197A) ja PKA(K72R)). Töö 
esimene osa kirjeldab viiruse elutsüklit, HPV valkude funktsioone ja PKA rolli raku- ja viiruse 
elutsüklis. Eksperimentaalne osa kirjeldab plasmiidide loomist, PKA valkude ekspressiooni 
taseme ja bioloogilise aktiivsuse analüüsi ja nende üle-ekspressiooni mõju erinevate HPV 
tüüpide replikatsioonile. Leiti, et PKA aktiivsus ei mõjuta HPV11 replikatsiooni U2OS 
rakuliinis, kuid HPV5 ja HPV18 replikatsioonid sõltuvad PKA aktiivsusest. Endogeense PKA 
aktivaatori IBMX (3-isobutüül-1-metüül-ksanteen) või aktiivse PKA üle-ekspressiooni 
tagajärjel oli HPV5 replikatsioon inhibeeritud, kuid üle-ekspresseeritud PKA suurendas HPV18 
replikatsiooni aktiivsust. Töö selgitab ka, et PKA fosforüleemine mõjutab HPV18 
replikatsiooni segatüüpi mehhanismi kaudu, kus üheks osaks on E8^E2 transkriptsioonilise 
repressori ekspressiooni vähendamine. Antud töö on tehtud Tartu Ülikooli 
Tehnoloogiainstituudis molekulaarse viroloogia uurimisrühmas. 
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SUPPLEMENTARY DATA 
Appendix 1. Primers used in the study 
№ Gene Gene bank 
accession number 
Primer Sequence 5’-3’ Product 
length 
1 PRKACA NM_001304349.1 
NM_002730.4 
NM_207518.3 
PKA A1 
F HindIII 
AAGCTTGGCAACGCCGC
CGCCGCCAAGA 
 
1064 
2 PKA A1 
R 
BamHI 
GGATCCCTAAAACTCAG
AAAACTCCTTG 
3 
 
PRKACA NM_001304349.1 
NM_002730.4 
NM_207518.3 
PKA A1 
T197A F 
GAAGGGCCGCACTTGGG
CCTTGTGCGGCACCCCT 
PKA A1 
T197A R 
AGGGGTGCCGCACAAGG
CCCAAGTGCGGCCCTTC 
4 PKA A1 
K72R F 
GAACCACTATGCCATGA
GGATCCTCGACAAACAG 
PKA A1 
K72R R 
CTGTTTGTCGAGGATCCT
CATGGCATAGTGGTTC 
5   GAPDH 
F 
CTCTCTGCTCCTCCTGTT
CGAC 
 
GAPDH 
R 
TGAGCGATGTGGCTCGG
CT 
6   HPV18 
E2 F 
GATAGTGGCTATGGCTG
TTC 
 
HPV18 
E2 R 
GCTGTTGTTGCCCTCTGT
G 
7   HPV18 
E1^E4 F 
CATTTACCAGCCCGACG
AG 
 
HPV18 
E1^E4 R 
GACGTCTGGCCGTAGGT
CTTTGC 
 61 
8   HPV18 
E8^E2 
MIX1 F 
GATAGTGGCTATGGCTG
TTC 
 
HPV18 
E8^E2 
MIX 1 R 
GACGTCTGGCCGTAGGT
CTTTGC 
9   HPV18 
E8^E2 
MIX 2 F 
CTGAAGTGGAAGCAACA
CAG 
 
HPV18 
E8^E2 
MIX 2 R 
GACGTCTGGCCGTAGGT
CTTTGC 
10 PRKACA NM_001304349.1 
NM_002730.4 
NM_207518.3 
PKA A 
F1 and 
R1 
CTTATACATGGTCATGG
AGTAC and 
CTGTAGATGAGATCCAG
CGAG 
149 
11 PKA A 
F2 and 
R2 
CTACCCGCCCTTCTTCGC
AGAC and 
CAAAGCGCTTGGTGAGA
TCTAC 
142 
12 PRKACB 
 
NM_001242857.2 
NM_001242858.2 
NM_001242859.2 
NM_001242860.2 
NM_001242861.2 
NM_001242862.2 
NM_001300915.2 
NM_001300916.2 
NM_001300917.2 
NM_002731.3 
NM_182948.4 
NM_207578.3 
 
PKA B 
F1 and 
R1 
GGGTGAAATGTTTTCAC
ATC and 
GATCTCTGTAGATGAGG
TCTAG 
124 
13 PKA B 
F2 and 
R2 
GGCAGAACTTGGACATT
ATGTG and 
GGTTGGTCTGCAAAGAA
TGG 
151 
 62 
14 PRKACG 
 
NM_002732.3 PKA G 
F1 and 
R1 
CTGCAGGTGGACCTCAC
CAAG and 
CGTCAAAGTTACTGGCA
TCCC 
168 
15 PKA G 
F2 and 
R2 
CTACAGCGCGTCGGAAG
GTTTAG and 
GAAGTCCGTCACCTGCA
GGTAG 
161 
16   pJET 1 F CGACTCACTATAGGGAG
AGCGGC 
 
pJET 2 R AAGAACATCGATTTTCC
ATGGCAG 
 
Explanatory note: yellow indicates the restriction sites.  
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